DPP-4抑制剂对糖耐量异常大鼠血糖的调节

目的观察DPP-4抑制剂用于糖耐量异常的大鼠是否可以逆转糖耐量受损的状况。方法构建糖耐量异常大鼠模型,在此基础上通过测定糖耐量实验前后葡萄糖浓度和胰岛素水平来观察磷酸西格列汀、阿格列汀对糖耐量异常大鼠血糖及胰岛素分泌的调节。结果西格列汀组和阿格列汀组与IGT组空腹血糖和空腹胰岛素水平相比,差异无统计学意义,糖负荷2 h后西格列汀组和阿格列汀组葡萄糖浓度低于IGT组,胰岛素水平高于IGT组,差异有统计学意义(P<0.05),西格列汀组和阿格列汀组与对照组相比无论是葡萄糖浓度还是胰岛素水平,差异均无统计学意义。同时西格列汀组和阿格列汀组相比,差异无统计学意义。结论磷酸西格列汀和阿格列汀均可改善糖耐量异常状态,同时促进糖耐量异常状态下胰岛功能的恢复。并无明显低血糖出现。

Objective To observe the DPP 4 inhibitors for abnormal glucose tolerance of impaired glucose tolerance in rats. Methods Build the rat model of abnormal glucose tolerance, and on this basis, through the determination of glucose tolerance of glucose and insulin levels before and after the experiment, to observe Sitagliptin; Alogliptin of glucose tolerance abnormal regulation of blood glucose and insulin secretion in rats. Results Sitagliptin and Alogliptin compared with IGT group of fasting plasma glucose and fasting insulin level has no statistical significance, Sitagliptin and Alogliptin with glucose concentrations below the IGT group, insulin levels higher than the IGT group on Glucose tolerance experiment 2 h, the difference was statistically significant （P〈0.05）;~ Sitagliptin and Alogliptin group compared with control group both glucose and insulin levels, there were no statistically significant difference. And Sitagliptin and Alogliptin group has no statistically significant difference. Conclusion Sitagliptin and Alogliptin can improve the glucose tolerance abnormal state, promote the recovery of islet function under the abnormal glucose tolerance, at the same time,there is no obvious hypoglycemic.